SpyGlass Pharma director buys SGP shares at $16

Khan Bilal Arshad, a director of SpyGlass Pharma, Inc., reported buying common stock in two open-market transactions on February 9, 2026 at $16 per share.

Rhea-AI Filing Summary

Khan Bilal Arshad, a director of SpyGlass Pharma, Inc., reported buying common stock in two open-market transactions on February 9, 2026 at $16 per share. He purchased 20,000 shares directly, bringing his direct holdings to 25,450 shares.

An affiliated entity, New World Medical, Inc., bought an additional 115,000 shares, increasing its indirect holdings reported for him to 251,427 shares. He is New World Medical’s Chief Executive Officer with voting and investment control but disclaims beneficial ownership of those shares except for his pecuniary interest.

Insider Trade Summary

Net Buyer: 135,000 shares

Net Buy 2 txns

Insider Khan Bilal Arshad

Role Director

Bought 135,000 shs ($2.16M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,000	$16.00	$320K
Purchase	Common Stock	115,000	$16.00	$1.84M

Holdings After Transaction: Common Stock — 25,450 shares (Direct); Common Stock — 251,427 shares (Indirect, See footnote)

Footnotes (1)

1. F1. Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for SpyGlass Pharma (SGP)?

Director Khan Bilal Arshad reported two open-market purchases of SpyGlass Pharma common stock on February 9, 2026 at $16 per share. One was a direct purchase of 20,000 shares, and the other was an indirect purchase of 115,000 shares through New World Medical, Inc.

How many SpyGlass Pharma (SGP) shares did the director buy directly?

He acquired 20,000 shares of SpyGlass Pharma common stock directly at $16 per share, raising his direct beneficial ownership to 25,450 shares. This direct position reflects shares held in his own name, separate from any entity-associated holdings reported as indirect ownership.

What is the indirect SpyGlass Pharma (SGP) ownership related to New World Medical, Inc.?

New World Medical, Inc. purchased 115,000 SpyGlass Pharma shares at $16 per share, bringing its indirectly reported holdings to 251,427 shares. Director Khan Bilal Arshad is New World Medical’s CEO, has voting and investment control, but disclaims beneficial ownership except for his pecuniary interest.

At what price were the SpyGlass Pharma (SGP) shares purchased?

Both the direct and indirect purchases of SpyGlass Pharma common stock were executed at $16 per share. This price applied to the 20,000 shares bought directly by the director and the 115,000 shares acquired indirectly through New World Medical, Inc. on February 9, 2026.

What roles does Khan Bilal Arshad hold in relation to SpyGlass Pharma (SGP) and New World Medical?

He serves as a director of SpyGlass Pharma, Inc. and as Chief Executive Officer of New World Medical, Inc. Through New World Medical, he has voting and investment control over its SpyGlass shares, while disclaiming beneficial ownership beyond his pecuniary interest in those shares.

How is indirect ownership of SpyGlass Pharma (SGP) shares disclosed in this filing?

Indirect ownership is disclosed through New World Medical, Inc., which holds 251,427 SpyGlass shares following the reported transaction. The filing explains the director’s role as CEO with voting and investment control, alongside a disclaimer that he only benefits to the extent of his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:07 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Bilal Arshad

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		P		20,000	A	$16	25,450	D
Common Stock	02/09/2026		P		115,000	A	$16	251,427	I	See footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.